GSK Expects Strong Annual Sales and Profits Amid European Tariffs
GSK anticipates its annual sales and profit to hit the top end of its forecast, considering current and expected tariffs on European goods. The company's second-quarter performance surpassed analyst predictions, thanks to its robust specialty medicine division.
GSK, the British pharmaceutical giant, announced on Wednesday its anticipation of reaching the upper limits of its annual sales and profit forecasts. This outlook takes into account existing and prospective tariffs affecting European goods.
The company attributed this positive forecast to its strong performance in the second quarter, where both sales and profits exceeded analysts' expectations. The success was largely driven by the vigor of its specialty medicine sector.
Such results highlight GSK's resilience and strategic growth in the face of global economic challenges, furthering its reputation in the pharmaceutical industry.
(With inputs from agencies.)
Advertisement
Google News